Table 2.
Exposure to olaratumab and doxorubicin
| Exposurea | Cohort 1 (N = 7b) | Cohort 2 (N = 6) | Cohort 3 (N = 6) |
|---|---|---|---|
| Olaratumab | |||
| Number of cycles | 4.0 (1‐29) | 9.5 (1‐20) | 7.0 (2‐23) |
| Duration on therapy (wks) | 12.7 (3‐91) | 29.5 (3‐61) | 22.2 (6‐72) |
| Cumulative dose (mg/kg) | 119.9 (2‐868) | 220.3 (30‐578) | 225.2 (71‐686) |
| Relative dose intensity (%) | 95.6 (5.0‐100.9) | 91.5 (59.9‐101.1) | 96.8 (93.7‐100.9) |
| Doxorubicin | |||
| Number of cycles | 4.5 (1‐6) | 6.0 (1‐6) | 5.0 (2‐6) |
| Duration on therapy (wks) | 14.1 (3‐23) | 18.6 (3‐23) | 15.8 (6‐20) |
| Cumulative dose (mg/m2) | 337.6 (76‐456) | 426.1 (75‐455) | 375.6 (151‐460) |
| Relative dose intensity (%) | 96.0 (78‐101) | 87.6 (71‐100) | 95.4 (90‐100) |
a
Data are median (range).
b
N = 6 for doxorubicin exposure in Cohort 1 as 1 patient, who experienced an infusion‐related reaction, did not receive doxorubicin.